Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850628 | ISIN: US46625H1005 | Ticker-Symbol: CMC
Tradegate
21.01.25
21:58 Uhr
252,80 Euro
+0,30
+0,12 %
1-Jahres-Chart
JPMORGAN CHASE & CO Chart 1 Jahr
5-Tage-Chart
JPMORGAN CHASE & CO 5-Tage-Chart
RealtimeGeldBriefZeit
251,65252,6521.01.
251,95253,0021.01.
PR Newswire
498 Leser
Artikel bewerten:
(2)

The Department of Health - Abu Dhabi: In coordination with DoH J.P. Morgan's Life Sciences Private Capital announces Life Sciences Innovation Summit 2024 finalists ahead of ADGHW

Finanznachrichten News

ABU DHABI, UAE, April 5, 2024 /PRNewswire/ -- Taking place on the sidelines of Abu Dhabi Global Healthcare Week (ADGHW), hosted by the Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, J.P. Morgan Asset Management's Life Sciences Private Capital, Blue Horizon Advisors and United AlSaqer Group announce the 11 finalists of the inaugural Life Sciences Innovation Summit 2024 on May 14 - 15, 2024.

Healthcare Innovation

The finalists were selected from a pool of exceptional candidates across more than 20 countries and represent a diverse range of companies and research institutions developing innovative therapeutic solutions. Each finalist has demonstrated a commitment to advancing healthcare through creativity and groundbreaking research, with the ultimate goal of addressing unmet patient needs for diseases of prevalence in the Middle East.

Finalists selected to compete in the summit include:

  • Algen Biotechnologies, Chun-Hao Huang, PhD, Co-Founder & CEO
  • AnaCardio, Patrik Strömberg, PhD, CEO
  • Chimera Therapeutics, Matthew Lorence, PhD, Co-Founder & CEO
  • Harmonic Discovery, Rayees Rahman, PhD, CEO
  • Lactocore, Anton Malyshev, PhD, Founder & CEO
  • Medicovestor, Seah Lim, PhD, CEO
  • Oncoheroes Biosciences, Cesare Spadoni, PhD, Co-Founder & Chief Operating Officer
  • Paradox Immunotherapeutics, Natalie Galant, PhD, Co-Founder & CEO
  • SaudiVax, Mazen Hassanain, PhD, CEO
  • Ypsilon Therapeutics, Dongxing Zha, PhD, Founder & CEO
  • ZTI Biosciences, Jaden Hyungseok Chang, PhD, CEO

Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: "We are very pleased to be partnering with the stellar leadership of the Department of Health - Abu Dhabi, Blue Horizon Advisors, United AlSaqer Group, Cleveland Clinic Abu Dhabi and other local leaders in launching our inaugural innovation summit."

Nabil Kobeissi, Chief Executive Officer, Blue Horizon Advisors added: "We are grateful to these preeminent scientists and business leaders for coming to Abu Dhabi to experience our growing innovation hub and meet these stellar finalists. With over 150 highly qualified applications submitted from around the globe, clearly the medical research and innovation community is paying attention to this event."

Dr. Asma Al Mannaei, the Executive Director of Research and Innovation Centre at the Department of Health - Abu Dhabi (DoH) said: "The hosting of the J.P. Morgan Asset Management Life Sciences Innovation Summit 2024 on the sidelines of Abu Dhabi Global Healthcare Week reflects the Department's dedication to transforming the regional healthcare ecosystem and accelerating innovation and healthcare outcomes. The Department of Health -

Abu Dhabi takes immense pride in fostering a disruptive environment where bright minds, researchers and innovators can bring forth groundbreaking solutions and treatments that contribute to the health and well-being of community members in Abu Dhabi and beyond. Abu Dhabi Global Healthcare Week aims to bring together innovators, investors and industry leaders to explore the latest advancements and trends shaping the future of healthcare. Reinforcing Abu Dhabi's position as a leading destination for life sciences and innovation, we look forward with excitement to ADGHW as we are confident it will mark a valuable starting point to a new era of collaboration with leading international partners on the global healthcare stage."

The finalists will be judged by an esteemed panel, which includes:

  • Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer Institute
  • Jorge Guzman, MD, CEO at Cleveland Clinic Abu Dhabi
  • Prof. Shahrukh Khurshid Hashmi, Director of Research at Department of Health, Abu Dhabi
  • David Hung, MD, Founder, President and CEO at Nuvation Bio
  • Yasmine Hayek Kobeissi, PhD, CQF, BSc., Executive Director at Blue Horizon Advisors
  • Anya Schiess, Managing Partner at J.P. Morgan Life Sciences Private Capital

In addition to the pitch competition, the summit will feature keynote speeches and networking opportunities to provide attendees with investment opportunities and valuable insights into the future of life sciences innovation. Learn more about the finalists and summit here.

ADGHW is a major government initiative from DoH held on 13th-15th May 2024, under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council. The event seeks to accelerate collaboration, innovation, and investment, and bring together researchers, policymakers, healthcare specialists, investors, and entrepreneurs across the global healthcare and life-science ecosystem.

Photo - https://mma.prnewswire.com/media/2380078/Healthcare_Innovation.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/in-coordination-with-doh-jp-morgans-life-sciences-private-capital-announces-life-sciences-innovation-summit-2024-finalists-ahead-of-adghw-302109217.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.